Inclusion Criteria:

          1. (ECOG) performance status of 0 or 1;

          2. Histologically confirmed lymphoma (tumor types are restricted to CLL, SLL, FL, MZL,
             LPL/WM, and MCL.)

          3. Patients with relapsed or refractory NHL for whom:

               -  Standard of care treatment options no longer exist (Stage 1 only)

               -  Standard of care treatment options no longer exist with the exception of
                  PI3K-delta inhibitors (Stage 2 only)

          4. Expected survival of more than 24 weeks

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from study entry:

          1. Primary central nervous system (CNS) lymphoma;

          2. Any of the following laboratory abnormalities Absolute neutrophil count <1.5×10^9/L,
             Hemoglobin <90 g/L Platelets <100 ×10^9/L

          3. Inadequate organ function, defined by the following:

               -  Total bilirubin ≥1.5 times the upper limit of normal (× ULN)

               -  AST or ALT > 2.5 × ULN

               -  Estimated creatinine clearance (CrCl) per Cockcroft-Gault

               -  Dose Escalation stage of trial (Stage 1) - CrCl < 50 mL/min

               -  Dose Expansion stage of trial (Stage 2) - CrCl <30 mL/min

          4. Clinically significant history of liver disease,

          5. Prior treatment with any PI3Kδ inhibitors

          6. Any prior use of the following: cancer therapy within 3 weeks of study treatment, GCSF
             within 7 days of screening, steroid therapy or targeted anti-neoplastic intent within
             7 days of treatment, any use of strong CYP3A4 inducers within 2 weeks prior to
             initiation of study treatment, prior autologous transplant within 6 months of study
             treatment, prior allogenic stem cell transplant within 6 months of study treatment,

          7. Clinically significant active infection

          8. Major surgical procedure within 4 weeks prior to initiation of study treatment;

          9. Adverse events from prior anti-neoplastic therapy that have not resolved to Grade less
             than or equal to 1, except for alopecia;

         10. New York Heart Association (NYHA) Class II or greater congestive heart failure

         11. Congenital long QT syndrome or QTc >470 msec;

         12. Currently use medication known to cause QT prolongation or torsades de pointes

         13. History of myocardial infarction or unstable angina within 6 months prior to
             initiation of study treatment;

         14. History of stroke or transient ischemic attack within 6 months prior to initiation of
             study treatment;

         15. Inability to take oral medication, prior surgical procedures affecting absorption, or
             active peptic ulcer disease;

         16. History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis);

         17. History of drug induced pneumonitis